BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/18/2020 2:20:37 PM | Browse: 747 | Download: 1242
 |
Received |
|
2020-06-23 13:19 |
|
Peer-Review Started |
|
2020-06-23 13:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-07-25 20:33 |
|
Revised |
|
2020-07-30 00:55 |
|
Second Decision |
|
2020-10-12 10:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-10-12 22:16 |
|
Articles in Press |
|
2020-10-12 22:16 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-10-18 20:31 |
|
Typeset the Manuscript |
|
2020-11-08 15:00 |
|
Publish the Manuscript Online |
|
2020-11-18 14:20 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Deep diving in the PACIFIC: Practical issues in stage III non-small-cell lung cancer to avoid shipwreck
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xabier Mielgo-Rubio, Federico Rojo, Laura Mezquita-Pérez, Francesc Casas, Amadeo Wals, Manel Juan, Carlos Aguado, Javier Garde-Noguera, David Vicente and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xabier Mielgo-Rubio, MD, Staff Physician, Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Calle Budapest 1, Alcorcón, Madrid 28922, Spain. xmielgo@hotmail.com |
| Key Words |
Durvalumab; Non-small-cell lung cancer; PACIFIC; Immunotherapy; Immune checkpoint inhibitors; Anti-programmed cell death ligand 1 |
| Core Tip |
Durvalumab consolidation therapy is the new standard of care in patients with unresectable stage III non-small cell lung cancer treated with concomitant chemoradiotherapy. In the PACIFIC trial, durvalumab significantly improved both progression-free and overall survival compared to placebo, with a manageable toxicity profile. However, several questions surrounding the clinical implementation of this therapy remain, including optimal patient selection and timing of treatment initiation, programmed cell death ligand 1 (PD-L1) determination, and the impact on clinical routines. These questions make interdisciplinary decision-making more necessary than ever. This review assesses these issues and future challenges from a multidisciplinary approach. |
| Publish Date |
2020-11-18 14:20 |
| Citation |
Mielgo-Rubio X, Rojo F, Mezquita-Pérez L, Casas F, Wals A, Juan M, Aguado C, Garde-Noguera J, Vicente D, Couñago F. Deep diving in the PACIFIC: Practical issues in stage III non-small-cell lung cancer to avoid shipwreck. World J Clin Oncol 2020; 11(11): 898-917 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i11/898.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i11.898 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
